Statistics

Total Visits

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results88

Select a period of time:

Number of views in the range

Views
Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results16

Views

Views
October 20257
November 20252
December 20252
January 20261
February 20261
March 20263
April 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
Argentina3
Venezuela2
United Kingdom2
Brazil1
Colombia1
Egypt1
 

Top cities views

Views
Buenos Aires1
Juazeiro do Norte1
Kintore1
La Guaira1
Los Polvorines1
Maracaibo1
Mendoza1
Minya1
San Antonio1
Santiago de Cali1